Can You Get GLP-1 Medications Without Diabetes?

    By Trimi Medical Team5 min read

    Yes, you can absolutely get GLP-1 medications without having diabetes. In fact, some of the most popular GLP-1 medications are FDA-approved specifically for chronic weight management in adults without diabetes. Understanding which medications are approved for which indications, and how to qualify, will help you navigate your options.

    Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. A healthcare provider must evaluate your individual situation to determine if GLP-1 therapy is appropriate for you.

    FDA-Approved GLP-1 Medications for Weight Loss (No Diabetes Required)

    • Wegovy (semaglutide 2.4 mg): Approved in 2021 for chronic weight management in adults with BMI 30+ or BMI 27+ with at least one weight-related comorbidity.
    • Zepbound (tirzepatide): Approved in 2023 for chronic weight management with the same BMI criteria as Wegovy.
    • Saxenda (liraglutide 3.0 mg): Approved in 2014 for chronic weight management with similar BMI requirements.

    Eligibility Criteria for Non-Diabetic Patients

    To qualify for a weight-loss GLP-1 prescription, you typically need:

    • BMI of 30 or higher (classified as obesity), regardless of other health conditions, OR
    • BMI of 27 or higher (classified as overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes or prediabetes, dyslipidemia (high cholesterol), obstructive sleep apnea, or cardiovascular disease.

    Some telehealth providers and compounding pharmacies may have slightly different criteria. At Trimi, our clinical team evaluates each patient individually to determine the best treatment approach.

    What About Ozempic and Mounjaro?

    Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for type 2 diabetes, not weight loss. However, they contain the same active ingredients as their weight-loss counterparts (Wegovy and Zepbound, respectively). Providers sometimes prescribe them off-label for weight loss, especially when the weight-loss versions are unavailable due to shortages.

    Compounded semaglutide and compounded tirzepatide are also available through licensed compounding pharmacies and do not carry the same indication restrictions, though they require a valid prescription from a licensed provider.

    How to Get Started

    • Telehealth consultation: Many patients access GLP-1 prescriptions through telehealth platforms like Trimi, which offer convenient online evaluations.
    • Primary care provider: Your regular doctor can prescribe weight-loss GLP-1 medications if you meet the criteria.
    • Weight management specialist: Obesity medicine physicians and endocrinologists frequently prescribe these medications.

    Frequently Asked Questions

    Can you get GLP-1 medications if you don't have diabetes?

    Yes. Several GLP-1 medications are FDA-approved specifically for weight management in non-diabetic patients. You typically need a BMI of 30+ or 27+ with a weight-related health condition to qualify.

    What BMI do you need for a GLP-1 prescription?

    For FDA-approved weight loss indications, you generally need a BMI of 30 or higher (obesity) or a BMI of 27 or higher with at least one weight-related comorbidity such as hypertension, high cholesterol, or sleep apnea.

    Is Ozempic prescribed for weight loss without diabetes?

    Ozempic is FDA-approved only for type 2 diabetes, but it is sometimes prescribed off-label for weight loss. Wegovy, which contains the same active ingredient (semaglutide) at a higher dose, is the FDA-approved weight loss version.

    Ready to find out if you qualify? Start your free eligibility check with Trimi today.

    Sources & References

    1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
    2. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
    3. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
    4. FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).

    Related Reading